MedTrace Logo

BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients

NCT01498172 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2015-02-04

No results posted yet for this study

Summary

In this study, the investigators would like to assess how intravesical BCG schedules after immunization of non muscle invasive bladder patients with the recMAGE-A3 protein, together with adjuvant AS15 (recMAGE-A3 + AS15 ASCI), may enhance innate and vaccine-specific T cell responses both systemically and locally in the bladder.

Conditions

Interventions

BIOLOGICAL

MAGE-A3 ASCI

5 doses every 3 weeks

BIOLOGICAL

BCG

1 intravesical dose /week for 6 weeks

Sponsors & Collaborators

  • Ludwig Center for Cancer Research of Lausanne

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Patrice Jichlinski

    lead OTHER

Principal Investigators

  • Patrice Jichlinski, MD · University Hospital Lausanne (CHUV)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2015-02-28

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01498172 on ClinicalTrials.gov